SATHGEN
State-of-the-art science for the hardest-to-treat cancers
Investment Highlights
Backed by established industrial conglomerates with a proven track record in healthcare and strong financial foundation for sustained growth.
Proven Market Potential
MSP008-22 has demonstrated compelling safety in Phase 1a trials with healthy volunteers and patients with solid tumors.
Robust IP Portfolio
Comprehensive global patent protection across multiple jurisdictions including USA, Europe, Japan, and emerging markets for sustained competitive advantage.
MSP008-22: Our Lead Asset
A first-in-class therapeutic with novel mechanism of action, currently in Phase I clinical trials with demonstrated efficacy across multiple cancer types and viral applications.
Phase I Initiation - Advanced Solid Tumors
Initiation of phase I trials of MSP008-22 in patients with advanced solid tumors and healthy volunteers.
First Cohort Completion
Completion of the dosing of the first cohort of patients in the phase I clinical trial of MSP008-22.
Studies Completed
Completed studies in healthy volunteers and patients.
Phase 1b/2
Clinical trials set to proceed onto phase 1b/2
Xenograft Studies
Xenograft studies with triple negative breast cancer cells show tumor growth inhibition upon single arm MSP008-22 or in combination with standard-of-care chemotherapy, Carboplatin.
Improved Efficacy
MSP008-22 improves the efficacy and lowers toxicity of another standard-of-care chemotherapy, Cisplatin, as shown by decreased IC50.
Safety Profile
MSP008-22 shows excellent safety profile in pre-clinical models including induced human blood lymphocytes.
Anti-Metastatic Efficacy
MSP008-22 also shows anti-stem cell and anti-metastatic efficacy in breast and prostate cancer models, in vitro.
Exceptional Investment Opportunity
Market-Leading Position
First-in-class mechanism targeting multiple high-value oncology indications with significant unmet medical need and market potential exceeding $10B globally.
De-Risked Investment
Strong preclinical data, active Phase I trials, comprehensive IP protection, and experienced management team with proven track record in drug development.
Global Expansion Ready
Established partnerships and regulatory pathways across major markets including US, Europe, and Asia-Pacific regions for rapid commercialization.
Key Metrics
Strategic Partnership Opportunities
We actively seek partnerships with pharmaceutical companies, research institutions, and investors to accelerate development and maximize global impact of our therapeutic programs.
Licensing Agreements
Regional or global licensing opportunities for MSP008-22 and pipeline compounds
Co-Development
Joint development programs with shared investment and risk mitigation strategies
Strategic Investment
Equity partnerships with pharmaceutical and biotech companies for mutual growth
Research Collaboration
Academic and industry partnerships for advancing novel therapeutic approaches
Connect With Our Team
Ready to discuss investment opportunities or strategic partnerships? Our experienced business development team is here to explore how we can work together.
Business Development
For partnership inquiries and investment opportunities
A Strong Base
Sathgen Therapeutics has strong financial and technical support to help achieve its goals. Drug discovery and clinical trials are conducted at Sathgen division of Godavari Biorefineries Limited (GBL), and linked to the Somaiya Group, which is actively involved in healthcare and education.